Efficacy Assessment of Celecoxib Oil Drops Versus Arachidonic Acid Stimulated Ophthalmic Inflammation in Rabbits

  • Anil K. Sharma
  • Prabhat K. Sahoo
  • Navneet Sharma
  • Rakesh K. Sharma
  • Amit Tyagi
Research Article


The most comfortable approach to deliver an active pharmaceutical ingredient to the eye has been via topical instillation of aqueous drops. However, the aqueous drops suffer a major setback due to the rapid drainage leading to loss of drug. The aim of the present work was to formulate oil preparations of celecoxib in different oils. Partition behavior, trans-corneal permeation, viscosity, in vivo anti-inflammatory study and gamma scintigraphy of the preparations were investigated. Incorporation of benzyl alcohol resulted in a significant increase in drug permeation across the cornea (p < 0.05). The in vivo efficacy of optimized castor oil formulation was found to be better than control as well as CXB-aqueous suspensions in arachidonic acid triggered eye swelling model in rabbits. Further, results of gamma scintigraphy also indicated prolonged retention. Therefore, the oil eye drops may be a promising alternative, to aqueous eye drops circumventing poor retention in management of ocular ailments.


Oil drops Trans-corneal permeation Arachidonic acid Protein estimation Gamma scintigraphy 



The acknowledgements are owed to Director, INMAS, Delhi for authorization to accomplish gamma scintigraphy experimentation. The authors are indebted for assistance offered by technical personnel and Dr. Ejan of Nuclear Medicine Department, INMAS, Delhi.

Compliance with Ethical Standards

Conflict of interest

There is no conflict of interest among authors for publishing this manuscript.


  1. 1.
    Abelson MB, Butrus SI, Kliman GH, Larson DL, Corey EJ, Smith LM (1987) Topical arachidonic acid: a model for screening anti-inflammatory agents. J Ocul Pharmacol 3:63–74CrossRefPubMedGoogle Scholar
  2. 2.
    Radi ZA, Render JA (2008) The pathophysiologic role of cyclooxygenases in the eye. J Ocul Pharmacol Ther 24(2):141–151CrossRefPubMedGoogle Scholar
  3. 3.
    Hersh PS, Rice BA, Baer JC, Wells PA, Lynch SE, McGuigan LJ et al (1990) Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol 108(4):577–583CrossRefPubMedGoogle Scholar
  4. 4.
    Searle AE, Pearce JL, Shaw DE (1990) Topical use of indomethacin on the day of cataract surgery. Br J Ophthalmol 74(1):19–21CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cooper CA, Bergamini MV, Leopold IH (1980) Use of flurbiprofen to inhibit corneal neovascularization. Arch Ophthalmol 98(6):1102–1105CrossRefPubMedGoogle Scholar
  6. 6.
    Malhotra M, Majumdar DK (1997) In vitro transcorneal permeation of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops. Indian J Exp Biol 35(9):941–947PubMedGoogle Scholar
  7. 7.
    Katara R, Majumdar DK (2013) Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery. Colloids Surf B Biointerfaces 103:455–462CrossRefPubMedGoogle Scholar
  8. 8.
    Kraff MC, Sanders DR, McGuigan L, Raanan MG (1990) Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Arch Ophthalmol 108(3):380–383CrossRefPubMedGoogle Scholar
  9. 9.
    McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96(1):272–277CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hecht G, Roehrs RE, Cooper ER, Hiddemen JW, VanDuzee BF (1990) Design and evaluation of ophthalmic pharmaceutical products. In: Banker GS, Rhodes CT (eds) Modern pharmaceutics, vol 40, 2nd edn. Marcel Dekker, New York, pp 539–603Google Scholar
  11. 11.
    Malhotra M, Majumdar DK (2006) Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note. AAPS PharmSciTech 7(4):96CrossRefPubMedGoogle Scholar
  12. 12.
    Pawar PK, Majumdar DK (2007) In vitro permeation characteristics of moxifloxacin from oil drops through excised goat, sheep, buffalo and rabbit corneas. Pharmazie 62:853–857PubMedGoogle Scholar
  13. 13.
    Ahuja M, Sharma SK, Majumdar DK (2007) In vitro corneal permeation of diclofenac from oil drops. Yakugaku Zasshi 127(10):1739–1745CrossRefPubMedGoogle Scholar
  14. 14.
    Sood R (1999) Medical laboratory technology: methods and interpretations. Jaypee Brothers, New Delhi, pp 169–177Google Scholar
  15. 15.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275PubMedGoogle Scholar
  16. 16.
    Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR (2005) Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech 6(1):E65–E73CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sharma AK, Sahoo PK, Majumdar DK, Sharma N, Sharma RK, Kumar A (2016) Fabrication and evaluation of lipid nanoparticulates for ocular delivery of a COX-2 inhibitor. Drug Deliv 23(9):3364–3373CrossRefPubMedGoogle Scholar
  18. 18.
    Ameeduzzafar, Ali J, Bhatnagar A, Kumar N, Ali A (2014) Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. Int J Biol Macromol 65:479–491CrossRefPubMedGoogle Scholar
  19. 19.
    Longer MA, Robinson JR (1990) In: Gennaro AR (ed) Remington’s pharmaceutical sciences, 18th edn. Mack Publishing Company, Easton, p 1687Google Scholar
  20. 20.
    Vieira C, Evangelista S, Cirillo R, Lippi A, Maggi CA, Manzini S (2000) Effect of ricinoleic acid in acute and subchronic experimental models of inflammation. Mediat Inflamm 9:223–228CrossRefGoogle Scholar

Copyright information

© The National Academy of Sciences, India 2017

Authors and Affiliations

  • Anil K. Sharma
    • 1
  • Prabhat K. Sahoo
    • 1
  • Navneet Sharma
    • 2
  • Rakesh K. Sharma
    • 2
  • Amit Tyagi
    • 2
  1. 1.Delhi Institute of Pharmaceutical Sciences and Research, Formerly College of Pharmacy, University of DelhiNew DelhiIndia
  2. 2.Division of CBRN DefenceInstitute of Nuclear Medicine and Allied SciencesDelhiIndia

Personalised recommendations